216 related articles for article (PubMed ID: 24573384)
1. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.
Kontro M; Kuusanmäki H; Eldfors S; Burmeister T; Andersson EI; Bruserud O; Brümmendorf TH; Edgren H; Gjertsen BT; Itälä-Remes M; Lagström S; Lohi O; Lundán T; Martí JM; Majumder MM; Parsons A; Pemovska T; Rajala H; Vettenranta K; Kallioniemi O; Mustjoki S; Porkka K; Heckman CA
Leukemia; 2014 Aug; 28(8):1738-42. PubMed ID: 24573384
[No Abstract] [Full Text] [Related]
2. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.
Bandapalli OR; Schuessele S; Kunz JB; Rausch T; Stütz AM; Tal N; Geron I; Gershman N; Izraeli S; Eilers J; Vaezipour N; Kirschner-Schwabe R; Hof J; von Stackelberg A; Schrappe M; Stanulla M; Zimmermann M; Koehler R; Avigad S; Handgretinger R; Frismantas V; Bourquin JP; Bornhauser B; Korbel JO; Muckenthaler MU; Kulozik AE
Haematologica; 2014 Oct; 99(10):e188-92. PubMed ID: 24972766
[No Abstract] [Full Text] [Related]
3. Targeting STAT5B in T-cell acute lymphoblastic leukemia.
Veloso A; Cools J
Blood; 2023 Jul; 142(3):215-217. PubMed ID: 37471110
[No Abstract] [Full Text] [Related]
4. Rare occurrence of a STAT5B N642H mutation in adult T-cell acute lymphoblastic leukemia.
Ma X; Wen L; Wu L; Wang Q; Yao H; Wang Q; Ma L; Chen S
Cancer Genet; 2015; 208(1-2):52-3. PubMed ID: 25749351
[No Abstract] [Full Text] [Related]
5. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.
Tremblay CS; Saw J; Boyle JA; Haigh K; Litalien V; McCalmont H; Evans K; Lock RB; Jane SM; Haigh JJ; Curtis DJ
Blood; 2023 Jul; 142(3):274-289. PubMed ID: 36989489
[TBL] [Abstract][Full Text] [Related]
6. Unveiling myeloid transformation: T-LGLL with eosinophilia masking myeloid-associated STAT5B mutation culminating in AML.
Dong Q; Wang Y; Xiu Y; Wu X; O'Neill S; Meyerson H; Suske T; Moriggl R; Hu S; Wang W; Zhao C
Br J Haematol; 2024 Jun; 204(6):2487-2491. PubMed ID: 38508872
[No Abstract] [Full Text] [Related]
7. Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.
Nagel S; Venturini L; Meyer C; Kaufmann M; Scherr M; Drexler HG; Macleod RA
Leuk Lymphoma; 2011 Feb; 52(2):290-7. PubMed ID: 21261500
[TBL] [Abstract][Full Text] [Related]
8. STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of
Van der Zwet JCG; Cordo' V; Buijs-Gladdines JGCAM; Hagelaar R; Smits WK; Vroegindeweij E; Graus LTM; Poort V; Nulle M; Pieters R; Meijerink JPP
Haematologica; 2023 Mar; 108(3):732-746. PubMed ID: 35734930
[TBL] [Abstract][Full Text] [Related]
9. The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.
Kampen KR; Sulima SO; Verbelen B; Girardi T; Vereecke S; Rinaldi G; Verbeeck J; Op de Beeck J; Uyttebroeck A; Meijerink JPP; Moorman AV; Harrison CJ; Spincemaille P; Cools J; Cassiman D; Fendt SM; Vermeersch P; De Keersmaecker K
Leukemia; 2019 Feb; 33(2):319-332. PubMed ID: 29930300
[TBL] [Abstract][Full Text] [Related]
10. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
[TBL] [Abstract][Full Text] [Related]
11. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P
Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704
[TBL] [Abstract][Full Text] [Related]
12. Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.
Vanden Bempt M; Demeyer S; Broux M; De Bie J; Bornschein S; Mentens N; Vandepoel R; Geerdens E; Radaelli E; Bornhauser BC; Kulozik AE; Meijerink JP; Bourquin JP; de Bock CE; Cools J
Cancer Cell; 2018 Aug; 34(2):271-285.e7. PubMed ID: 30107177
[TBL] [Abstract][Full Text] [Related]
13. BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?
Kawashima-Goto S; Imamura T; Tomoyasu C; Yano M; Yoshida H; Fujiki A; Tamura S; Osone S; Ishida H; Morimoto A; Kuroda H; Hosoi H
PLoS One; 2015; 10(7):e0132926. PubMed ID: 26172269
[TBL] [Abstract][Full Text] [Related]
14. Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.
Suske T; Sorger H; Manhart G; Ruge F; Prutsch N; Zimmerman MW; Eder T; Abdallah DI; Maurer B; Wagner C; Schönefeldt S; Spirk K; Pichler A; Pemovska T; Schweicker C; Pölöske D; Hubanic E; Jungherz D; Müller TA; Aung MMK; Orlova A; Pham HTT; Zimmel K; Krausgruber T; Bock C; Müller M; Dahlhoff M; Boersma A; Rülicke T; Fleck R; de Araujo ED; Gunning PT; Aittokallio T; Mustjoki S; Sanda T; Hartmann S; Grebien F; Hoermann G; Haferlach T; Staber PB; Neubauer HA; Look AT; Herling M; Moriggl R
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618957
[TBL] [Abstract][Full Text] [Related]
15. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.
Zuurbier L; Petricoin EF; Vuerhard MJ; Calvert V; Kooi C; Buijs-Gladdines JG; Smits WK; Sonneveld E; Veerman AJ; Kamps WA; Horstmann M; Pieters R; Meijerink JP
Haematologica; 2012 Sep; 97(9):1405-13. PubMed ID: 22491738
[TBL] [Abstract][Full Text] [Related]
16. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
17. Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia.
Heltemes-Harris LM; Larson JD; Starr TK; Hubbard GK; Sarver AL; Largaespada DA; Farrar MA
Oncogene; 2016 Jun; 35(26):3454-64. PubMed ID: 26500062
[TBL] [Abstract][Full Text] [Related]
18. BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia.
Olesinski EA; Bhatia KS; Mahesh AN; Rosli S; Mohamed JS; Jen WY; Jain N; Garcia JS; Wong GC; Ooi M; Letai A; Konopleva M; Bhatt S
Blood Adv; 2023 Jun; 7(12):2917-2923. PubMed ID: 36763538
[No Abstract] [Full Text] [Related]
19. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.
Bodaar K; Yamagata N; Barthe A; Landrigan J; Chonghaile TN; Burns M; Stevenson KE; Devidas M; Loh ML; Hunger SP; Wood B; Silverman LB; Teachey DT; Meijerink JP; Letai A; Gutierrez A
Leukemia; 2022 Jun; 36(6):1499-1507. PubMed ID: 35411095
[TBL] [Abstract][Full Text] [Related]
20. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.
Ribeiro D; Melão A; van Boxtel R; Santos CI; Silva A; Silva MC; Cardoso BA; Coffer PJ; Barata JT
Blood Adv; 2018 Sep; 2(17):2199-2213. PubMed ID: 30185437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]